Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen Dose Optimization by TCF20 Genotype in Breast Cancer
NCT04961632Phase 1Active, not recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Dec 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tamoxifen in breast cancer (2 arms), sponsored by National Cancer Centre Singapore. Primary endpoint: Endoxifen blood concentration at 8 weeks. Started Dec 2020; status: active, not recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04961632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961632.